iBio, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that iBio, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Jun 30, 2023 | $0 | Sep 27, 2023 |
| FY2023 | Jun 30, 2022 | $1.88M | Sep 27, 2023 |
| FY2022 | Jun 30, 2021 | $2.37M | Oct 11, 2022 |
| FY2021 | Jun 30, 2020 | $1.64M | Sep 28, 2021 |
| FY2020 | Jun 30, 2019 | $2.02M | Oct 13, 2020 |
| FY2019 | Jun 30, 2018 | $444.0K | Aug 26, 2019 |
| FY2018 | Jun 30, 2017 | $394.0K | Sep 18, 2018 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $400.0K | Sep 5, 2025 |
| FY2025 | Jun 30, 2024 | $225.0K | Sep 5, 2025 |
| FY2024 | Jun 30, 2023 | $0 | Sep 24, 2024 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Jun 30, 2017 | $394.0K | Sep 15, 2017 |
| FY2017 | Jun 30, 2016 | $948.0K | Sep 15, 2017 |
| FY2016 | Jun 30, 2015 | $1.85M | Oct 13, 2016 |
| FY2015 | Jun 30, 2014 | $205.0K | Oct 13, 2015 |
| FY2014 | Jun 30, 2013 | $1.01M | Sep 29, 2014 |
| FY2013 | Jun 30, 2012 | $1.28M | Oct 4, 2013 |
| FY2012 | Jun 30, 2011 | $520.1K | Oct 15, 2012 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Jun 30, 2022 | $2.17M | Oct 11, 2022 |
| FY2022 | Jun 30, 2021 | $909.0K | Oct 11, 2022 |
| FY2021 | Jun 30, 2020 | $935.0K | Sep 28, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($18.38M) | Sep 5, 2025 |
| FY2025 | Jun 30, 2024 | ($24.91M) | Sep 5, 2025 |
| FY2024 | Jun 30, 2023 | ($65.01M) | Sep 24, 2024 |
| FY2022 | Jun 30, 2022 | ($50.30M) | Oct 11, 2022 |
| FY2022 | Jun 30, 2021 | ($23.21M) | Oct 11, 2022 |
| FY2021 | Jun 30, 2020 | ($16.44M) | Sep 28, 2021 |
| FY2020 | Jun 30, 2019 | ($17.59M) | Oct 13, 2020 |
| FY2019 | Jun 30, 2018 | ($16.11M) | Aug 26, 2019 |
| FY2018 | Jun 30, 2017 | ($14.53M) | Sep 18, 2018 |
| FY2017 | Jun 30, 2016 | ($9.76M) | Sep 15, 2017 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($18.60M) | Sep 5, 2025 |
| FY2025 | Jun 30, 2024 | ($16.63M) | Sep 5, 2025 |
| FY2024 | Jun 30, 2023 | ($29.34M) | Sep 24, 2024 |
| FY2023 | Jun 30, 2022 | ($29.70M) | Sep 27, 2023 |
| FY2022 | Jun 30, 2021 | ($31.11M) | Oct 11, 2022 |
| FY2021 | Jun 30, 2020 | ($14.00M) | Sep 28, 2021 |
| FY2020 | Jun 30, 2019 | ($15.79M) | Oct 13, 2020 |
| FY2019 | Jun 30, 2018 | ($14.23M) | Aug 26, 2019 |
| FY2018 | Jun 30, 2017 | ($14.27M) | Sep 18, 2018 |
| FY2017 | Jun 30, 2016 | ($9.89M) | Sep 15, 2017 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $8.31M | Sep 5, 2025 |
| FY2025 | Jun 30, 2024 | $5.19M | Sep 5, 2025 |
| FY2024 | Jun 30, 2023 | $10.33M | Sep 24, 2024 |
| FY2023 | Jun 30, 2022 | $9.83M | Sep 27, 2023 |
| FY2022 | Jun 30, 2021 | $9.99M | Oct 11, 2022 |
| FY2021 | Jun 30, 2020 | $3.57M | Sep 28, 2021 |
| FY2020 | Jun 30, 2019 | $5.47M | Oct 13, 2020 |
| FY2019 | Jun 30, 2018 | $3.99M | Aug 26, 2019 |
| FY2018 | Jun 30, 2017 | $4.12M | Sep 18, 2018 |
| FY2017 | Jun 30, 2016 | $3.16M | Sep 15, 2017 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($15.30M) | Sep 5, 2025 |
| FY2025 | Jun 30, 2024 | ($18.55M) | Sep 5, 2025 |
| FY2024 | Jun 30, 2023 | ($30.44M) | Sep 24, 2024 |
| FY2023 | Jun 30, 2022 | ($37.48M) | Sep 27, 2023 |
| FY2022 | Jun 30, 2021 | ($30.06M) | Oct 11, 2022 |
| FY2021 | Jun 30, 2020 | ($13.35M) | Sep 28, 2021 |
| FY2020 | Jun 30, 2019 | ($13.98M) | Oct 13, 2020 |
| FY2019 | Jun 30, 2018 | ($13.48M) | Aug 26, 2019 |
| FY2018 | Jun 30, 2017 | ($13.16M) | Sep 18, 2018 |
| FY2013 | Jun 30, 2013 | ($4.85M) | Oct 4, 2013 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $16.0K | Sep 5, 2025 |
| FY2025 | Jun 30, 2024 | $210.0K | Sep 5, 2025 |
| FY2024 | Jun 30, 2023 | $5.74M | Sep 24, 2024 |
| FY2023 | Jun 30, 2022 | $7.33M | Sep 27, 2023 |
| FY2022 | Jun 30, 2021 | $4.92M | Oct 11, 2022 |
| FY2021 | Jun 30, 2020 | $1.08M | Sep 28, 2021 |
| FY2020 | Jun 30, 2019 | $920.0K | Oct 13, 2020 |
| FY2019 | Jun 30, 2018 | $934.0K | Aug 26, 2019 |
| FY2018 | Jun 30, 2017 | $1.32M | Sep 18, 2018 |
| FY2017 | Jun 30, 2016 | $68.0K | Sep 15, 2017 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $23.19M | Sep 5, 2025 |
| FY2025 | Jun 30, 2024 | $28.73M | Sep 5, 2025 |
| FY2024 | Jun 30, 2023 | $41.21M | Sep 24, 2024 |
| FY2023 | Jun 30, 2022 | $99.41M | Sep 27, 2023 |
| FY2022 | Jun 30, 2021 | $146.97M | Oct 11, 2022 |
| FY2021 | Jun 30, 2020 | $94.19M | Sep 28, 2021 |
| FY2020 | Mar 31, 2020 | $42.22M | Oct 13, 2020 |
| FY2020 | Jun 30, 2019 | $30.59M | Oct 13, 2020 |
| FY2019 | Jun 30, 2018 | $43.08M | Aug 26, 2019 |
| FY2018 | Jun 30, 2017 | $36.01M | Sep 18, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $8.31M | Sep 5, 2025 |
| FY2025 | Jun 30, 2024 | $7.41M | Sep 5, 2025 |
| FY2024 | Jun 30, 2023 | $25.83M | Sep 24, 2024 |
| FY2023 | Jun 30, 2022 | $35.92M | Sep 27, 2023 |
| FY2022 | Jun 30, 2021 | $38.40M | Oct 11, 2022 |
| FY2021 | Jun 30, 2020 | $37.58M | Sep 28, 2021 |
| FY2020 | Jun 30, 2019 | $28.13M | Oct 13, 2020 |
| FY2019 | Jun 30, 2018 | $26.92M | Aug 26, 2019 |
| FY2018 | Jun 30, 2017 | $27.10M | Sep 18, 2018 |
| FY2017 | Jun 30, 2016 | $27.56M | Sep 15, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $14.88M | Sep 5, 2025 |
| FY2025 | Jun 30, 2024 | $21.32M | Sep 5, 2025 |
| FY2024 | Jun 30, 2023 | $15.38M | Sep 24, 2024 |
| FY2023 | Jun 30, 2022 | $63.49M | Sep 27, 2023 |
| FY2022 | Jun 30, 2021 | $108.59M | Oct 11, 2022 |
| FY2021 | Jun 30, 2020 | $56.62M | Sep 28, 2021 |
| FY2020 | Jun 30, 2019 | $2.46M | Oct 13, 2020 |
| FY2019 | Jun 30, 2018 | $16.17M | Aug 26, 2019 |
| FY2018 | Jun 30, 2017 | $8.91M | Sep 18, 2018 |
| FY2017 | Jun 30, 2016 | $9.94M | Sep 15, 2017 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($332.22M) | Sep 5, 2025 |
| FY2025 | Jun 30, 2024 | ($313.85M) | Sep 5, 2025 |
| FY2024 | Jun 30, 2023 | ($288.94M) | Sep 24, 2024 |
| FY2023 | Jun 30, 2022 | ($223.93M) | Sep 27, 2023 |
| FY2022 | Jun 30, 2021 | ($173.63M) | Oct 11, 2022 |
| FY2021 | Jun 30, 2020 | ($150.42M) | Sep 28, 2021 |
| FY2020 | Jun 30, 2019 | ($105.82M) | Oct 13, 2020 |
| FY2019 | Jun 30, 2018 | ($88.23M) | Aug 26, 2019 |
| FY2018 | Jun 30, 2017 | ($72.12M) | Sep 18, 2018 |
| FY2017 | Jun 30, 2016 | ($57.59M) | Sep 15, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $8.58M | Sep 5, 2025 |
| FY2025 | Jun 30, 2024 | $14.21M | Sep 5, 2025 |
| FY2024 | Jun 30, 2023 | $4.30M | Sep 24, 2024 |
| FY2023 | Jun 30, 2022 | $22.68M | Sep 27, 2023 |
| FY2022 | Jun 30, 2021 | $77.40M | Oct 11, 2022 |
| FY2021 | Jun 30, 2020 | $55.11M | Sep 28, 2021 |
| FY2021 | Jun 30, 2019 | $4.42M | Sep 28, 2021 |
| FY2020 | Jun 30, 2018 | $4.42M | Oct 13, 2020 |
| FY2019 | Jun 30, 2017 | $15.93M | Aug 26, 2019 |
| FY2020 | Jun 30, 2016 | $15.93M | Oct 13, 2020 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | (1) | Sep 5, 2025 |
| FY2025 | Jun 30, 2024 | (6) | Sep 5, 2025 |
| FY2024 | Jun 30, 2023 | (106) | Sep 24, 2024 |
| FY2023 | Jun 30, 2022 | (5) | Sep 27, 2023 |
| FY2022 | Jun 30, 2021 | (3) | Oct 11, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | (1) | Sep 5, 2025 |
| FY2025 | Jun 30, 2024 | (6) | Sep 5, 2025 |
| FY2024 | Jun 30, 2023 | (106) | Sep 24, 2024 |
| FY2023 | Jun 30, 2022 | (5) | Sep 27, 2023 |
| FY2022 | Jun 30, 2021 | (3) | Oct 11, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | 19.35M | Sep 5, 2025 |
| FY2025 | Jun 30, 2024 | 8.62M | Sep 5, 2025 |
| FY2024 | Jun 30, 2023 | 1.02M | Sep 24, 2024 |
| FY2023 | Jun 30, 2022 | 8.73M | Sep 27, 2023 |
| FY2022 | Jun 30, 2021 | 8.71M | Oct 11, 2022 |
| FY2021 | Jun 30, 2020 | 140.07M | Sep 28, 2021 |
| FY2020 | Jun 30, 2019 | 20.15M | Oct 13, 2020 |
| FY2019 | Jun 30, 2018 | 16.04M | Aug 26, 2019 |
| FY2018 | Jun 30, 2017 | 8.91M | Sep 18, 2018 |
| FY2017 | Mar 31, 2017 | 89.12M | Sep 15, 2017 |